Clinical Trials Browser

Phase 3 × INDUSTRY × tremelimumab × Clear all

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03298451 2026-03-20

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT05883644 2026-02-18

SIERRA

Phase 3 Active not recruiting

Gastrointestinal

Liver Neoplasms

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Urothelial Cancer

NCT06921785 2026-01-09

ARTEMIDE-HCC01

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 3 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 3 FDA

Small Cell Lung Carcinoma

NCT05557838 2025-02-07

TREMENDOUS

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02352948 2024-07-26

ARCTIC

Phase 3 Completed

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

NCT03084471 2022-12-22

STRONG

Phase 3 Completed

867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT02551159 2021-10-13

KESTREL

Phase 3 Completed

823 enrolled 23 charts

Squamous Cell Carcinoma of Head and Neck

NCT02369874 2021-02-10

EAGLE

Phase 3 Completed

736 enrolled 26 charts

Head and Neck Neoplasms, Recurrence

NCT00257205 2012-07-02

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Phase 3 Completed

Melanoma